The TT genotype is found in 17% of healthy controls, but only in 5% of patients with coronary atherosclerosis—3% for Group A and 7% for Group B. CD14 C260T promoter polymorphism could be implicated in protective pathways against CAD. This evidence concerns the gene CD14 and coronary atherosclerosis.